**Supplementary Information**

异质

**Supplemental Fig. 1** (A) Comparison of all-cause death between short- term DAPT and long- term DAPT after removal of one trials, (B) Comparison of major bleeding between short- term DAPT and long- term DAPT after removal of one trials.

亚组


**Supplemental Fig. 2** Subgroup analysis for each outcome. (A) all cause death, (B) major bleeding, (C) cardiovascular death, (D) myocardial infarction, (E) definite or probable stent thrombosis, (F) stroke.


labe**Supplemental Fig. 3** Labbe plot of major bleeding.

星状图**Supplemental Fig. 4** Galbraith plot of major bleeding.

TSA

**Supplemental Fig. 5** The required information size for each outcome. (A) all cause death, (B) major bleeding, (C) cardiovascular death, (D) myocardial infarction, (E) definite or probable stent thrombosis.





**Supplemental Fig. 6** Assessing risk of bias for each trial included.

漏斗

**Supplemental Fig. 7** The funnel plot for each outcome. (A) all cause death, (B) major bleeding, (C) cardiovascular death, (D) myocardial infarction, (E) definite or probable stent thrombosis, (F) stroke.

**Supplemental Table 1.** Thesearch strategy of PubMed.

|  |  |  |
| --- | --- | --- |
| **#** | **Searches** | **Results** |
| **#1** | **drug eluting stent [MeSH Terms]** | **11637** |
| **#2** | **"drug eluting stent "[tiab] OR "DES "[tiab] OR "percutaneous coronary intervention "[tiab] OR "percutaneous coronary interventions "[tiab] OR "percutaneous coronary revascularization "[tiab] OR "percutaneous coronary revascularizations "[tiab] OR "PCI "[tiab]** | **69654** |
| **#3** | **Dual Anti-Platelet Therapies [MeSH Terms]** | **112** |
| **#4** | **"Dual Anti Platelet Therapy "[tiab] OR "Dual Anti-Platelet Therapies "[tiab] OR "DAPT "[tiab]** | **2704** |
| **#5** | **(drug eluting stent [MeSH Terms]) OR ("drug eluting stent "[tiab] OR "DES "[tiab] OR "percutaneous coronary intervention "[tiab] OR "percutaneous coronary interventions "[tiab] OR "percutaneous coronary revascularization "[tiab] OR "percutaneous coronary revascularizations "[tiab] OR "PCI "[tiab])** | **74219** |
| **#6** | **(Dual Anti-Platelet Therapies [MeSH Terms]) OR ("Dual Anti Platelet Therapy "[tiab] OR "Dual Anti-Platelet Therapies "[tiab] OR "DAPT "[tiab])** | **2761** |
| **#7** | **((drug eluting stent [MeSH Terms]) OR ("drug eluting stent "[tiab] OR "DES "[tiab] OR "percutaneous coronary intervention "[tiab] OR "percutaneous coronary interventions "[tiab] OR "percutaneous coronary revascularization "[tiab] OR "percutaneous coronary revascularizations "[tiab] OR "PCI "[tiab])) AND ((Dual Anti-Platelet Therapies [MeSH Terms]) OR ("Dual Anti Platelet Therapy "[tiab] OR "Dual Anti-Platelet Therapies "[tiab] OR "DAPT "[tiab]))** | **1131** |
| **#8** | **((drug eluting stent [MeSH Terms]) OR ("drug eluting stent "[tiab] OR "DES "[tiab] OR "percutaneous coronary intervention "[tiab] OR "percutaneous coronary interventions "[tiab] OR "percutaneous coronary revascularization "[tiab] OR "percutaneous coronary revascularizations "[tiab] OR "PCI "[tiab])) AND ((Dual Anti-Platelet Therapies [MeSH Terms]) OR ("Dual Anti Platelet Therapy "[tiab] OR "Dual Anti-Platelet Therapies "[tiab] OR "DAPT "[tiab]))** Filters: **Randomized Controlled Trial** | **157** |

**Supplemental Table 2.** Thesearch strategy of EMBASE.

|  |  |  |
| --- | --- | --- |
| **#** | **Searches** | **Results** |
| **#1** | **'drug eluting stent':ab,ti OR 'des':ab,ti OR 'percutaneous coronary intervention':ab,ti OR 'percutaneous coronary interventions':ab,ti OR 'percutaneous coronary revascularization':ab,ti OR 'percutaneous coronary revascularizations':ab,ti OR 'pci':ab,ti** | **137997** |
| **#2** | **'dapt':ab,ti OR 'anti-platelet therapies, dual':ab,ti OR 'dual anti platelet therapy':ab,ti OR 'dual anti-platelet therapies':ab,ti** | **5399** |
| **#3** | **'rct':ab,ti OR 'randomized controlled trial':ab,ti OR 'randomised':ab,ti OR 'clinical trials, randomized':ab,ti OR 'trials, randomized clinical':ab,ti OR 'controlled clinical trials, randomized':ab,ti** | **275967** |
| **#4** | **#1 AND #2** | **2340** |
| **#5** | **#3 AND #4** | **155** |

**Supplemental Table 3.** The search strategy of Cochrane Library.

|  |  |  |
| --- | --- | --- |
| **#** | **Searches** | **Results** |
| **#1** | **MeSH descriptor: [Drug-Eluting Stents] explode all trees** | **1398** |
| **#2** | **((drug eluting stent);ti,ab,kw OR (DES);ti,ab,kw OR (percutaneous coronary intervention);ti,ab,kw OR (percutaneous coronary interventions);ti,ab,kw OR (percutaneous coronary revascularization);ti,ab,kw OR (percutaneous coronary revascularizations);ti,ab,kw OR (PCI);ti,ab,kw):ti,ab,kw** | **16565** |
| **#3** | **MeSH descriptor: [Dual Anti-Platelet Therapy] explode all trees** | **14** |
| **#4** | **((DAPT);ti,ab,kw OR (Anti-Platelet Therapies, Dual);ti,ab,kw OR (Dual Anti Platelet Therapy);ti,ab,kw OR (Dual Anti-Platelet Therapies);ti,ab,kw):ti,ab,kw** | **901** |
| **#5** | **#1 OR #2** | **16906** |
| **#6** | **#3 OR #4** | **901** |
| **#7** | **#5 AND #6** | **586** |

**Supplemental Table 4.** Summary of GRADE evidence quality for outcomes.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Efficacy and Safety of Short-Term Dual Antiplatelet Therapy After New DES Implementation in East Asian for New DES Implementation in East Asian** | | | | | | |
| **Patient or population:** patients with New DES Implementation in East Asian **Settings:** **Intervention:**Efficacy and Safety of Short-Term Dual Antiplatelet Therapy After New DES Implementation in East Asian | | | | | | |
| **Outcomes** | **Illustrative comparative risks\* (95% CI)** | | **Relative effect (95% CI)** | **No of Participants (studies)** | **Quality of the evidence (GRADE)** |  |
| Assumed risk | Corresponding risk |
|  | **Control** | **Efficacy and Safety of Short-Term Dual Antiplatelet Therapy After New DES Implementation in East Asian** |  |  |  |  |
| **All-cause death** Follow-up: 12-18 months | **Study population** | | **RR 1.03** (0.76 to 1.39) | 15688 (6 studies) | **⊕⊕⊕⊕** **high** |  |
| **11 per 1000** | **11 per 1000** (8 to 15) |
| **Moderate** | |
| **12 per 1000** | **12 per 1000** (9 to 17) |
| **Major bleeding** Follow-up: 12-18 months | **Study population** | | **RR 0.64** (0.49 to 0.85) | 15688 (6 studies) | **⊕⊕⊕⊝** **moderate1** |  |
| **16 per 1000** | **10 per 1000** (8 to 14) |
| **Moderate** | |
| **10 per 1000** | **6 per 1000** (5 to 9) |
| **Myocardial infarction** Follow-up: mean 12-18 months | **Study population** | | **RR 0.97** (0.72 to 1.31) | 15688 (6 studies) | **⊕⊕⊕⊕** **high** |  |
| **11 per 1000** | **10 per 1000** (8 to 14) |
| **Moderate** | |
| **9 per 1000** | **9 per 1000** (6 to 12) |
| **Stent thrombosis** Follow-up: mean 12-18 months | **Study population** | | **RR 1.52** (0.83 to 2.78) | 15688 (6 studies) | **⊕⊕⊕⊕** **high** |  |
| **2 per 1000** | **3 per 1000** (2 to 6) |
| **Moderate** | |
| **2 per 1000** | **3 per 1000** (2 to 6) |
| **cardiovascular death** Follow-up: mean 12-18 months | **Study population** | | **RR 0.83** (0.55 to 1.24) | 15688 (6 studies) | **⊕⊕⊕⊕** **high** |  |
| **6 per 1000** | **5 per 1000** (4 to 8) |
| **Moderate** | |
| **8 per 1000** | **7 per 1000** (4 to 10) |
| **Stroke** Follow-up: mean 12-18 months | **Study population** | | **RR 0.90** (0.61 to 1.31) | 15688 (6 studies) | **⊕⊕⊕⊕** **high** |  |
| **7 per 1000** | **6 per 1000** (4 to 9) |
| **Moderate** | |
| **5 per 1000** | **4 per 1000** (3 to 7) |
| \*The basis for the**assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect**of the intervention (and its 95% CI).  **CI:**Confidence interval; **RR:**Risk ratio; | | | | | | |
| GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:**Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate. | | | | | | |
| 1 moderate heterogeneity for major bleeding | | | | | | |

**Supplemental Table 5.** The *P* value of Begg’s and Egger’s for each outcome.

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | | All cause  death | Major  bleeding | Cardiovascular  death | Myocardial infarction | Definite or  probable stent  thrombosis | Stroke |
| Begg’s Test | adj. kendall’s  Score (P-Q) | | -1 | 5 | -1 | -1 | -1 | 5 |
|  | Std. Dev. of Score | | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 |
|  | Number of studies | | 6 | 6 | 6 | 6 | 6 | 6 |
|  | Z | | -0.19 | 0.94 | -0.19 | -0.19 | -0.19 | 0.94 |
|  | Pr ＞∣z∣ | | 0.851 | 0.348 | 0.851 | 0.851 | 0.851 | 0.348 |
|  | Z(continuity corrected) | | 0.00 | 0.75 | 0.00 | 0.00 | 0.00 | 0.75 |
|  | Pr ＞∣z∣(continuity corrected) | | 1.000 | 0.452 | 1.000 | 1.000 | 1.000 | 0.452 |
| Egger’s Test | Coef. | slope | .3734942 | -.6345046 | .1660593 | -.0068986 | .7261601 | -1.621716 |
| bias | -.94888 | .6347804 | -.6962496 | -.0678009 | -.3873252 | 3.028597 |
| Std. err. | slope | .6487032 | .7558419 | .7629977 | .4247139 | .6408509 | 1.153159 |
| bias | 1.698514 | 2.120401 | 1.466538 | 1.116358 | .8195629 | 2.365354 |
| t | slope | 0.58 | -0.84 | 0.22 | -0.02 | 1.13 | -1.41 |
| bias | -0.56 | 0.30 | -0.47 | -0.06 | -0.47 | 1.28 |
| p ＞∣t∣ | slope | 0.596 | 0.448 | 0.838 | 0.988 | 0.320 | 0.232 |
| bias | 0.606 | 0.780 | 0.660 | 0.954 | 0.661 | 0.270 |
| [95%Conf. Interval] | slope | -1.427595 | -2.733058 | -1.952362 | -1.186093 | -1.053127 | 4.8234 |
| bias | -5.664711 | -5.252395 | -4.768013 | -3.167307 | -2.662796 | -3.538679 |
|  | slope | 2.174583 | 1.464049 | 2.28448 | 1.172296 | 2.505447 | 1.579967 |
|  | bias | 3.766951 | 6.521956 | 3.375513 | 3.031705 | 1.888146 | 9.595874 |